The role of the Microarray Core will be to carry out genome-wide analyses of transcriptional changes and of gene copy number changes that result from either experimentally induced or clinically arising aberrations in genes that regulate genomic stability, cell survival, cell cycle signaling and developmental maturation in T cell oncogenesis. Gene expression profiling will be carried out on specimens from projects 1, 2 and 4, as a means to discover the transcriptional consequences of perturbing molecules that are critical in these processes. Array Comparative Genomic Hybridization will be performed to detect and quantify gene loss and gene amplification in tumors from experimental animals in project 4. It is anticipated that both types of microarray studies will identify genes whose activity, and in some cases, structure, are disrupted by abnormalities in the key regulatory proteins involved in T cell malignancy. The following services will be provided by the Microarray Core: 1. Starting with RNA provided by investigators, produce transcriptional profiling data using mouse or human oligonucleotide microarrays. 2. Starting with genomic DNA provided by investigators, produce genomewide gene copy number determinations using mouse or human oligonucleotide microarrays.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA109901-03
Application #
7250865
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
3
Fiscal Year
2006
Total Cost
$104,520
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Mansour, Marc R; He, Shuning; Li, Zhaodong et al. (2018) JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. J Exp Med 215:1929-1945
Winter, Georg E; Mayer, Andreas; Buckley, Dennis L et al. (2017) BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Mol Cell 67:5-18.e19
Erb, Michael A; Scott, Thomas G; Li, Bin E et al. (2017) Transcription control by the ENL YEATS domain in acute leukaemia. Nature 543:270-274
Lobbardi, Riadh; Pinder, Jordan; Martinez-Pastor, Barbara et al. (2017) TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia. Cancer Discov 7:1336-1353
Rahman, Sunniyat; Magnussen, Michael; León, Theresa E et al. (2017) Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia. Blood 129:3221-3226
Abraham, Brian J; Hnisz, Denes; Weintraub, Abraham S et al. (2017) Small genomic insertions form enhancers that misregulate oncogenes. Nat Commun 8:14385
Li, Z; Abraham, B J; Berezovskaya, A et al. (2017) APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL. Leukemia 31:2057-2064
Akahane, K; Sanda, T; Mansour, M R et al. (2016) HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia. Leukemia 30:219-28
Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M et al. (2016) Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol 12:876-84
Hnisz, Denes; Weintraub, Abraham S; Day, Daniel S et al. (2016) Activation of proto-oncogenes by disruption of chromosome neighborhoods. Science 351:1454-1458

Showing the most recent 10 out of 63 publications